References

Huntingtin‐lowering therapies for huntington disease: a review of the evidence of potential benefits and risks

10.1001/jamaneurol.2020.0299 · ExternalCitation · doi-reference

Building CRISPR gene therapies for the central nervous system: a review

10.1001/jamaneurol.2023.4983 · ExternalCitation · doi-reference

Lipid nanoparticles enhance mRNA delivery to the central nervous system upon intrathecal injection

10.1002/adma.202417097 · ExternalCitation · doi-reference

Clinical pharmacology and translational considerations in the development of CRISPR‐based therapies

10.1002/cpt.3000 · ExternalCitation · doi-reference

40+ years of the Huntington disease predictive genetic testing protocol: recommendations for an update

10.1002/jgc4.70226 · ExternalCitation · doi-reference

10.1007/978-3-031-73363-5_56

10.1007/978-3-031-73363-5_56 · ExternalCitation · doi-reference

Clinical features of Huntington's disease

10.1007/978-3-319-71779-1_1 · ExternalCitation · doi-reference

Unintended CRISPR‐Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene‐editing in human cells

10.1007/s00439-023-02561-1 · ExternalCitation · doi-reference

CRISPR/Cas9 mediated therapeutic approach in huntington's disease

10.1007/s12035-022-03150-5 · ExternalCitation · doi-reference

CRISPR‐based genome‐editing tools for Huntington's disease research and therapy

10.1007/s12264-022-00880-3 · ExternalCitation · doi-reference

Lipid nanoparticles deliver mRNA to the blood–brain barrier

10.1007/s12274-024-6827-7 · ExternalCitation · doi-reference

Therapeutic validation of MMR‐associated genetic modifiers in a human ex vivo model of Huntington disease

10.1016/j.ajhg.2024.04.015 · ExternalCitation · doi-reference

Gene targeting techniques for Huntington's disease

10.1016/j.arr.2021.101385 · ExternalCitation · doi-reference

Engineering adeno‐associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing

10.1016/j.biomaterials.2025.123314 · ExternalCitation · doi-reference

An insight into allele‐selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

10.1016/j.biopha.2024.117557 · ExternalCitation · doi-reference

Cpf1 is a single RNA‐guided endonuclease of a class 2 CRISPR‐Cas system

10.1016/j.cell.2015.09.038 · ExternalCitation · doi-reference

Transcriptome engineering with RNA‐targeting type VI‐D CRISPR effectors

10.1016/j.cell.2018.02.033 · ExternalCitation · doi-reference

A Huntingtin knockin pig model recapitulates features of selective neurodegeneration in Huntington's disease

10.1016/j.cell.2018.03.005 · ExternalCitation · doi-reference

CAG repeat not polyglutamine length determines timing of Huntington's disease onset

10.1016/j.cell.2019.06.036 · ExternalCitation · doi-reference

CRISPR‐based therapeutic genome editing: strategies and in vivo delivery by AAV vectors

10.1016/j.cell.2020.03.023 · ExternalCitation · doi-reference

Heritable human genome editing: research progress, ethical considerations, and hurdles to clinical practice

10.1016/j.cell.2021.02.036 · ExternalCitation · doi-reference

Engineered virus‐like particles for efficient in vivo delivery of therapeutic proteins

10.1016/j.cell.2021.12.021 · ExternalCitation · doi-reference

Past, present, and future of CRISPR genome editing technologies

10.1016/j.cell.2024.01.042 · ExternalCitation · doi-reference

Long somatic DNA‐repeat expansion drives neurodegeneration in Huntington's disease

10.1016/j.cell.2024.11.038 · ExternalCitation · doi-reference

Unbiased profiling of isogenic Huntington disease hPSC‐derived CNS and peripheral cells reveals strong cell‐type specificity of CAG length effects

10.1016/j.celrep.2019.02.008 · ExternalCitation · doi-reference

Negative autoregulation mitigates collateral RNase activity of repeat‐targeting CRISPR‐Cas13d in mammalian cells

10.1016/j.celrep.2022.111226 · ExternalCitation · doi-reference

Chemically modified guide RNAs enhance CRISPR‐Cas13 knockdown in human cells

10.1016/j.chembiol.2021.07.011 · ExternalCitation · doi-reference

Comparative analysis of lipid nanoparticle‐mediated delivery of CRISPR‐Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo

10.1016/j.ejpb.2024.114207 · ExternalCitation · doi-reference

Molecular mechanisms of RNA targeting by Cas13‐containing type VI CRISPR‐Cas systems

10.1016/j.jmb.2018.06.029 · ExternalCitation · doi-reference

Cas13d is a compact RNA‐targeting type VI CRISPR effector positively modulated by a WYL‐domain‐containing accessory protein

10.1016/j.molcel.2018.02.028 · ExternalCitation · doi-reference

The biology of huntingtin

10.1016/j.neuron.2016.02.003 · ExternalCitation · doi-reference

PAM‐altering SNP‐based allele‐specific CRISPR‐Cas9 therapeutic strategies for Huntington's disease

10.1016/j.omtm.2022.08.005 · ExternalCitation · doi-reference

A novel class of self‐complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR

10.1016/j.omtm.2024.101206 · ExternalCitation · doi-reference

CRISPR‐Cas9‐mediated genome editing increases lifespan and improves motor deficits in a Huntington's disease mouse model

10.1016/j.omtn.2019.07.009 · ExternalCitation · doi-reference

CRISPR interference efficiently induces specific and reversible gene silencing in human iPSCs

10.1016/j.stem.2016.01.022 · ExternalCitation · doi-reference

Reversal of phenotypic abnormalities by CRISPR/Cas9‐mediated gene correction in Huntington disease patient‐derived induced pluripotent stem cells

10.1016/j.stemcr.2017.01.022 · ExternalCitation · doi-reference

The potential of gene editing for Huntington's disease

10.1016/j.tins.2023.02.005 · ExternalCitation · doi-reference

CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo

10.1016/j.ymthe.2016.11.010 · ExternalCitation · doi-reference

Mutation‐independent allele‐specific editing by CRISPR‐Cas9, a novel approach to treat autosomal dominant disease

10.1016/j.ymthe.2020.05.002 · ExternalCitation · doi-reference

Single‐base resolution: increasing the specificity of the CRISPR‐Cas system in gene editing

10.1016/j.ymthe.2020.11.009 · ExternalCitation · doi-reference

Di‐valent siRNA‐mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington's disease

10.1016/j.ymthe.2023.05.006 · ExternalCitation · doi-reference

Treatment of Huntington's disease with a pan‐HTT‐targeting CRISPR nuclease

10.1016/j.ymthe.2026.04.038 · ExternalCitation · doi-reference

A biological classification of Huntington's disease: the integrated staging system

10.1016/s1474-4422(22)00120-x · ExternalCitation · doi-reference

Potential disease‐modifying therapies for Huntington's disease: lessons learned and future opportunities

10.1016/s1474-4422(22)00121-1 · ExternalCitation · doi-reference

Brain nucleic acid delivery and genome editing via focused ultrasound‐mediated blood–brain barrier opening and long‐circulating nanoparticles

10.1021/acsnano.4c05270 · ExternalCitation · doi-reference

DNA targeting specificity of RNA‐guided Cas9 nucleases

10.1038/nbt.2647 · ExternalCitation · doi-reference

Repair of double‐strand breaks induced by CRISPR‐Cas9 leads to large deletions and complex rearrangements

10.1038/nbt.4192 · ExternalCitation · doi-reference

CRISPR interference (CRISPRi) for sequence‐specific control of gene expression

10.1038/nprot.2013.132 · ExternalCitation · doi-reference

Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics

10.1038/s12276-023-01086-x · ExternalCitation · doi-reference

Therapeutic in vivo genome editing: innovations and challenges in rAAV vector‐based CRISPR delivery

10.1038/s41434-025-00573-2 · ExternalCitation · doi-reference

CRISPR‐Cas12a induced DNA double‐strand breaks are repaired by multiple pathways with different mutation profiles in Magnaporthe oryzae

10.1038/s41467-022-34736-1 · ExternalCitation · doi-reference

Huntington's disease cellular phenotypes are rescued non‐cell autonomously by healthy cells in mosaic telencephalic organoids

10.1038/s41467-024-50877-x · ExternalCitation · doi-reference

Cas9‐mediated replacement of expanded CAG repeats in a pig model of Huntington's disease

10.1038/s41551-023-01007-3 · ExternalCitation · doi-reference

Blood‐brain‐barrier‐crossing lipid nanoparticles for mRNA delivery to the central nervous system

10.1038/s41563-024-02114-5 · ExternalCitation · doi-reference

Customizable virus‐like particles deliver CRISPR–Cas9 ribonucleoprotein for effective ocular neovascular and Huntington's disease gene therapy

10.1038/s41565-024-01851-7 · ExternalCitation · doi-reference

Drug delivery systems for CRISPR‐based genome editors

10.1038/s41573-023-00762-x · ExternalCitation · doi-reference

Lipid nanoparticles for mRNA delivery

10.1038/s41578-021-00358-0 · ExternalCitation · doi-reference

Huntington disease: somatic expansion, pathobiology and therapeutics

10.1038/s41582-025-01159-7 · ExternalCitation · doi-reference

High‐fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects

10.1038/s41587-022-01419-7 · ExternalCitation · doi-reference

Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR‐Cas9 ribonucleoprotein

10.1038/s41587-024-02437-3 · ExternalCitation · doi-reference

Precise RNA targeting with CRISPR‐Cas13d

10.1038/s41587-025-02558-3 · ExternalCitation · doi-reference

Chromothripsis as an on‐target consequence of CRISPR–Cas9 genome editing

10.1038/s41588-021-00838-7 · ExternalCitation · doi-reference

In vivo CRISPR‐Cas9 genome editing in mice identifies genetic modifiers of somatic CAG repeat instability in Huntington's disease

10.1038/s41588-024-02054-5 · ExternalCitation · doi-reference

Base editing of trinucleotide repeats that cause Huntington's disease and Friedreich's ataxia reduces somatic repeat expansions in patient cells and in mice

10.1038/s41588-025-02172-8 · ExternalCitation · doi-reference

Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease highlight shared and tissue‐specific effects

10.1038/s41588-025-02191-5 · ExternalCitation · doi-reference

High prevalence of Streptococcus pyogenes Cas9‐reactive T cells within the adult human population

10.1038/s41591-018-0204-6 · ExternalCitation · doi-reference

Identification of preexisting adaptive immunity to Cas9 proteins in humans

10.1038/s41591-018-0326-x · ExternalCitation · doi-reference

Pre‐existing adaptive immunity to the RNA‐editing enzyme Cas13d in humans

10.1038/s41591-022-01848-6 · ExternalCitation · doi-reference

Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington's disease decades before clinical motor diagnosis

10.1038/s41591-024-03424-6 · ExternalCitation · doi-reference

An RNA‐targeting CRISPR‐Cas13d system alleviates disease‐related phenotypes in Huntington's disease models

10.1038/s41593-022-01207-1 · ExternalCitation · doi-reference

Collateral activity of the CRISPR/RfxCas13d system in human cells

10.1038/s42003-023-04708-2 · ExternalCitation · doi-reference

DNA double‐strand break‐free CRISPR interference delays Huntington's disease progression in mice

10.1038/s42003-023-04829-8 · ExternalCitation · doi-reference

CRISPR‐Cas9 in vivo gene editing for transthyretin amyloidosis

10.1056/nejmoa2107454 · ExternalCitation · doi-reference

Setting ethical limits on human gene editing after the fall of the somatic/germline barrier

10.1073/pnas.2004837117 · ExternalCitation · doi-reference

Focused ultrasound‐mediated brain genome editing

10.1073/pnas.2302910120 · ExternalCitation · doi-reference

Circumventing the packaging limit of AAV‐mediated gene replacement therapy for neurological disorders

10.1080/14712598.2022.2012148 · ExternalCitation · doi-reference

Regulatory considerations for clinical trial applications with CRISPR‐based medicinal products

10.1089/crispr.2021.0148 · ExternalCitation · doi-reference

Immune responses and immunosuppressive strategies for adeno‐associated virus‐based gene therapy for treatment of central nervous system disorders: current knowledge and approaches

10.1089/hum.2022.138 · ExternalCitation · doi-reference

Limitations of dual‐single guide RNA CRISPR strategies for the treatment of central nervous system genetic disorders

10.1089/hum.2023.109 · ExternalCitation · doi-reference

Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study

10.1093/brain/awab190 · ExternalCitation · doi-reference

Exon 1‐targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models

10.1093/brain/awae266 · ExternalCitation · doi-reference

An enhanced Q175 knock‐in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes

10.1093/hmg/ddw212 · ExternalCitation · doi-reference

FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat

10.1093/hmg/ddy375 · ExternalCitation · doi-reference

Highly efficient RNA‐guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins

10.1101/gr.171322.113 · ExternalCitation · doi-reference

Huntington's disease: a clinical review

10.1111/ene.13413 · ExternalCitation · doi-reference

Lipid nanoparticles for mRNA delivery in brain via systemic administration

10.1126/sciadv.adw0730 · ExternalCitation · doi-reference

Self‐inactivating AAV‐CRISPR at different ages enables sustained amelioration of Huntington's disease deficits in BAC226Q mice

10.1126/sciadv.aea8052 · ExternalCitation · doi-reference

C2c2 is a single‐component programmable RNA‐guided RNA‐targeting CRISPR effector

10.1126/science.aaf5573 · ExternalCitation · doi-reference

RNA editing with CRISPR‐Cas13

10.1126/science.aaq0180 · ExternalCitation · doi-reference

Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease

10.1126/scitranslmed.aat7108 · ExternalCitation · doi-reference

Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease

10.1126/scitranslmed.abc2888 · ExternalCitation · doi-reference

Antisense oligonucleotide‐mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington's disease iPSC‐derived striatal neurons

10.1126/scitranslmed.adn4600 · ExternalCitation · doi-reference

CRISPR/Cas9‐mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease

10.1172/jci92087 · ExternalCitation · doi-reference

Current and possible future therapeutic options for Huntington's disease

10.1177/11795735221092517 · ExternalCitation · doi-reference

Recent progress and considerations for AAV gene therapies targeting the central nervous system

10.1186/s11689-018-9234-0 · ExternalCitation · doi-reference

Designing and optimizing AAV‐mediated gene therapy for neurodegenerative diseases: from bench to bedside

10.1186/s12967-024-05661-2 · ExternalCitation · doi-reference

RNA‐targeting CRISPR/CasRx system relieves disease symptoms in Huntington's disease models

10.1186/s13024-024-00794-w · ExternalCitation · doi-reference

Huntington's disease mouse models: unraveling the pathology caused by CAG repeat expansion

10.12703/r/10-77 · ExternalCitation · doi-reference

Global huntingtin knockout in adult mice leads to fatal neurodegeneration that spares the pancreas

10.26508/lsa.202402571 · ExternalCitation · doi-reference

Family communication patterns and challenges of Huntington's disease risk, the decision to pursue presymptomatic testing, and test results

10.3233/jhd-200402 · ExternalCitation · doi-reference

Large animal models of Huntington's disease: what we have learned and where we need to go next

10.3233/jhd-200425 · ExternalCitation · doi-reference

DNA mismatch repair and its role in Huntington's disease

10.3233/jhd-200438 · ExternalCitation · doi-reference

Immunogenicity and toxicity of AAV gene therapy

10.3389/fimmu.2022.975803 · ExternalCitation · doi-reference

Huntingtin and the synapse

10.3389/fncel.2021.689332 · ExternalCitation · doi-reference

Huntingtin exon 1 deletion does not alter the subcellular distribution of huntingtin and gene transcription in mice

10.3389/fncel.2022.1021592 · ExternalCitation · doi-reference

Patient‐specific iPSC‐based models of Huntington's disease as a tool to study store‐operated calcium entry drug targeting

10.3389/fphar.2018.00696 · ExternalCitation · doi-reference

Generation of rhesus macaque embryos with expanded CAG trinucleotide repeats in the huntingtin gene

10.3390/cells13100829 · ExternalCitation · doi-reference

Chronic in vivo CRISPR‐Cas genome editing: challenges, long‐term safety, and outlook

10.3390/cells15020156 · ExternalCitation · doi-reference

Generation of new isogenic models of Huntington's disease using CRISPR‐Cas9 technology

10.3390/ijms21051854 · ExternalCitation · doi-reference

CRISPR/Cas9 landscape: current state and future perspectives

10.3390/ijms242216077 · ExternalCitation · doi-reference

Immune toxicities in AAV gene therapy: overview for clinicians

10.3390/ijms27073196 · ExternalCitation · doi-reference

CRISPR‐Cas13: pioneering RNA editing for nucleic acid therapeutics

10.34133/bdr.0041 · ExternalCitation · doi-reference

10.64898/2026.08.10.744034

10.64898/2026.08.10.744034 · ExternalCitation · doi-reference

Base editing strategies to convert CAG to CAA diminish the disease‐causing mutation in Huntington's disease

10.7554/elife.89782.2 · ExternalCitation · doi-reference